Future studies should prioritize multicenter cohorts to expand tumor subgroup analyses, integrate longitudinal receptor activator of nuclear factor-kappa B ligand/osteoprotegerin monitoring with imaging, elucidate chemotherapy-induced osteotoxicity mechanisms, and test multimodal interventions (antiresorptives, tailored exercise, nutritional support) for fracture prevention in cancer survivors. This evidence concerns the gene TNFRSF11B and cancer.